Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Exploiting neointimal and vascular smooth muscle cell heterogeneity to reveal mechanisms driving venous neointimal growth and vascular remodeling in pediatric pulmonary hypertension

Award Number: K08HL173632
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 05/05/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Exploiting neointimal and vascular smooth muscle cell heterogeneity to reveal mechanisms driving venous neointimal growth and vascular remodeling in pediatric pulmonary hypertension - Abstract Pediatric Pulmonary hypertension (PPH) is a progressive and incurable disease hallmarked by abnormal development, muscularization and blockage of small pulmonary vessels by the formation of obstructive ‘neointimal lesions’. While most research has focused on arterial disease, venous changes including neointima, are described in nearly all forms of PPH but little is known about what controls vein neointima formation. Available therapies do not target lesion growth, neither prevent nor reverse disease, and are contraindicated when vein remodeling predominates. Early evidence suggests novel heterogeneity among pulmonary vascular smooth muscle cells (VSMCs) and neointima, but the molecular control and contribution of these subsets in PPH remains unknown. Understanding the biology of post-capillary vascular remodeling and, more generally, how heterogeneous VSMC and neointimal subsets contribute to PPH has the potential to significantly advance the understanding of the cellular and molecular controls of pathologic vascular remodeling in PPH. In Aim 1, Dr. Lea Steffes will train with mentors Dr. Maya Kumar in mouse transgenics, cutting-edge imaging and quantitation techniques and Dr. Mark Krasnow in advanced biocomputational analysis to define transcriptomic heterogeneity between pre- and post-capillary neointima and provide the first genomic-wide characterization of vein neointima. In addition to an in vivo pharmacologic inhibition study in mice using tools developed and published by Drs. Steffes and Kumar, in Aim 2, Dr. Steffes will train with advisor Dr. David Cornfield to perform a broad in vitro screen of VSMC growth modulators on vein neointima cells. With training in human pulmonary vascular histopathology from advisors Drs. Serena Tan and Csaba Galambos, Aim 3 will connect Dr. Steffes’s research and clinical expertise by interrogating the role of two novel developmental VSMC subsets in heritable PPH. The Candidate Training Plan provides a complimentary skillset of in vitro investigation, bio-computational analysis, and human lung vascular histopathology training to interrogate the cell-specific behaviors and molecular signatures of pathologic cell types (vein neointima, Aims 1&2 and developmental VSMC subsets, Aim3) integral to PPH. Mentor Dr. Maya Kumar is a thought-leader in the use of advanced mouse genetics and genomic tools to interrogate pathologic pulmonary vascular biology. Co-mentor Dr. Mark Krasnow (single cell analysis) and advisors Dr. David Cornfield (in vitro analysis) and Dr. Serena Tan (human lung histopathology) and Dr. Csaba Galambos (pediatric PPH pathology) offer complementary expertise. The environment at Stanford University is renowned for collaborative and innovative research. Supported by this infrastructure, candidate Dr. Steffes has demonstrated tremendous academic growth with 9 publications including 5 as first-author since 2020. In summary, this strong mentoring environment and training plan are anticipated to fully prepare Dr. Steffes to launch her independent career. The proposed studies will offer mechanistic insights into pediatric pulmonary vascular pathogenesis, and may identify therapeutic targets to improve the lives of children with PPH.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $164,543 )
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Lung Diseases Research	001	3	6/2/2026	NON-COMPETING CONTINUATION	$0
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Lung Diseases Research	000	3	5/22/2026	NON-COMPETING CONTINUATION	$164,543
														Subtotal = $164,543

Issue Date FY: 2025 ( Subtotal = $165,231 )
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Lung Diseases Research	000	2	3/27/2025	NON-COMPETING CONTINUATION	$165,231
														Subtotal = $165,231

Issue Date FY: 2024 ( Subtotal = $165,996 )
2024	2024	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Lung Diseases Research	000	1	5/5/2024	NEW	$165,996
														Subtotal = $165,996

Grand Total All Awards = $495,770

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploiting neointimal and vascular smooth muscle cell heterogeneity to reveal mechanisms driving venous neointimal growth and vascular remodeling in pediatric pulmonary hypertension

Award Number: K08HL173632

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 05/05/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer